We appreciate the interest of Dr Schulze-Koops and colleagues in our article.1 The role of the inflammatory rheumatic diseases (IRDs), their therapies and other potential factors in the risk of… Click to show full abstract
We appreciate the interest of Dr Schulze-Koops and colleagues in our article.1 The role of the inflammatory rheumatic diseases (IRDs), their therapies and other potential factors in the risk of SARS-CoV-2 infection and course of COVID-19 disease are a topic in a constant update. In this sense, we consider that our study provides additional evidence in patients with IRD regarding susceptibility to moderate-severe infection related to COVID-19.2 It is important to note that SARS-CoV-2/COVID-19 is a very changing epidemiological scenario. Our manuscript is a real-world longitudinal study performed during the period of maximum health emergency due to the COVID-19 pandemic in Madrid, the epicentre of the outbreak in Spain. We included all patients …
               
Click one of the above tabs to view related content.